FROM Katie Thomas
Can politics cure the high cost of drugs? EpiPens are the poster child for vast increases in the price of familiar medications. Many people carry them for emergency treatment of allergic reactions that can be life threatening. So, when the Mylan Company raised the price of two EpiPens from $100 $614 it made big news. Turns out, it's the tip of the iceberg. Drug prices are on the rise and desperately ill people are often those hit by bills they never expected. Other countries have established price controls for life-or-death medications, but America's system is so complex it defies understanding. Drug and insurance companies, hospitals and doctors engage in secret negotiations, while various middlemen get cuts of the action. And, who's paying for those expensive ads on TV? Patients. Are the presidential campaigns offering any realistic solutions?
Shoddy Practices at Big Drug Makers So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues." Katie Thomas covers the business of healthcare for the New York Times .
House Republicans release their Obamacare replacement As two House committees take up "repeal and replacement" of "Obamacare," there may be life left in the Affordable Care Act after all. Even Republicans are divided, and proposed changes won't make good on President Trump's promise to provide "health insurance for everybody."
Nationalism's appeal on both sides of the Atlantic Nationalism, Populism, concerns about immigration and outright racism are part of election campaigns from the US to Europe. We hear how today's election in Holland reflects the recent past and may forecast the future.
America's top diplomat faces challenges in Asia Whatever happened to America's "pivot to Asia?" That's just one of the questions left hanging since Rex Tillerson's first trip there as Secretary of State. Is the Trump Administration hoping to change Foreign Policy or maintain the status quo?